Mc Callion Orla
Conseiller Juridique Général chez ULTIMOVACS ASA
Profil
Mc Callion Orla is currently the Head of Regulatory Affairs & QA at Ultimovacs ASA since 2021.
Prior to this, he worked as the Director of Regulatory Affairs at OxThera AB from 2012 to 2021.
Dr. Orla holds a doctorate degree from Queen's University.
Postes actifs de Mc Callion Orla
| Sociétés | Poste | Début |
|---|---|---|
| ULTIMOVACS ASA | Conseiller Juridique Général | 01/10/2021 |
Anciens postes connus de Mc Callion Orla
| Sociétés | Poste | Fin |
|---|---|---|
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Conseiller Juridique Général | 01/10/2021 |
Formation de Mc Callion Orla
| Queen's University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ULTIMOVACS ASA | Health Technology |
| Entreprise privées | 1 |
|---|---|
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |